Rambus Initiates $100 Million Accelerated Share Repurchase Program

Rambus Initiates $100 Million Accelerated Share Repurchase Program

Rambus Inc. (NASDAQ: RMBS), a premier chip and silicon IP provider making data faster and safer, today announced that it initiated an accelerated share repurchase program with Mizuho Markets Americas LLC, through its agent Mizuho Securities USA LLC ("Dealer") to repurchase an aggregate of approximately $100 million of its common stock.

"This accelerated share repurchase reflects our confidence in the business and reinforces our commitment to disciplined capital allocation," said Luc Seraphin, president and chief executive officer at Rambus. "Supported by the strength of our balance sheet and continued cash generation, we remain focused on increasing stockholder value while investing in the long-term growth of the company."

Under the accelerated share repurchase program, Rambus will pre-pay $100 million to Dealer and receive an initial delivery of approximately 796,000 shares of its common stock. The final number of shares to be repurchased will be determined based on the volume-weighted average price of Rambus common stock during the term of the transaction, less a discount. The program is expected to be completed by the end of the third quarter of 2026.

The accelerated share repurchase program is part of the broader share repurchase program previously authorized by the Rambus Board of Directors.

About Rambus Inc.

Rambus delivers industry-leading chips and silicon IP for the data center and AI infrastructure. With over three decades of advanced semiconductor experience, our products and technologies address the critical bottlenecks between memory and processing to accelerate data-intensive workloads. By enabling greater bandwidth, efficiency and security across next generation computing platforms, we make data faster and safer. For more information, visit rambus.com.

Forward-Looking Statements

This release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995 relating, among other things, to the terms of Rambus' accelerated share repurchase program, including timing. Such forward-looking statements are based on current expectations, estimates and projections, management's beliefs and certain assumptions made by Rambus' management. Actual results may differ materially. The forward-looking statements contained in this press release are subject to risks and uncertainties, including those more fully described in Rambus' Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The forward-looking statements in this press release are based on information available to Rambus as of the date hereof, and Rambus undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date hereof.

Related Links

https://www.rambus.com/

Nicole Noutsios
Rambus Investor Relations
(510) 315-1003
rambus@nmnadvisors.com

News Provided by Business Wire via QuoteMedia

RMBS
The Conversation (0)
Tencent Announces Winners of Flagship CarbonX Program to Combat Climate Change

Tencent Announces Winners of Flagship CarbonX Program to Combat Climate Change

Tencent (00700.HK) is awarding 13 exceptional teams that won the first phase of its groundbreaking CarbonX Program which is aimed at boosting promising new climate technologies. The winners, which emerged from a pool of 30 finalists and more than 300 initial applications, will receive a total of... Keep Reading...
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC Degrader of EGFR L858R for NSCLC

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC Degrader of EGFR L858R for NSCLC

C4 Therapeutics to Receive a $10 Million Upfront Payment, a $25 Million Equity Investment and is Eligible to Receive up to $357 Million for Development and Commercial Milestones Plus Royalties on Net Sales in Greater China Betta Pharmaceuticals to Develop and Commercialize CFT8919 in Greater... Keep Reading...
International Lithium Announces Maiden Mineral Resource Estimate at The Raleigh Lake Lithium Project, Ontario, Canada

International Lithium Announces Maiden Mineral Resource Estimate at The Raleigh Lake Lithium Project, Ontario, Canada

International Lithium Corp. (TSXV: ILC) (OTCQB: ILHMF) (FSE: IAH) (the "Company" or "ILC") is pleased to announce a maiden Mineral Resource Estimate ("MRE") for the Raleigh Lake Lithium Project ("Raleigh Lake", "The Property", the "Project"), located approximately 25 km west of Ignace, Ontario,... Keep Reading...
Change Of Non-Executive Directors; Resignation of Executive Director; Change of Composition of Board Committee; And Change of Authorized Representative

Change Of Non-Executive Directors; Resignation of Executive Director; Change of Composition of Board Committee; And Change of Authorized Representative

SouthGobi Resources Ltd. (TSX:SGQ)(HK:1878) ("SouthGobi" or the "Company") announces that is pleased to announce the following changes in the composition of the Company's board (the "Board") of directors (the "Director(s)"), with effect from December 6, 2022: (i) Mr. Zhiwei Chen ("Mr. Chen") and... Keep Reading...

VOX PROVIDES DEVELOPMENT & EXPLORATION UPDATES

Vox Royalty Corp. (TSXV: VOX) (OTCQX: VOXCF ) (" Vox " or the " Company "), a high growth precious metals focused royalty company, is pleased to provide recent development and exploration updates from royalty operating partners ValOre Metals Corp. (TSXV: VO) (" ValOre "), Genesis Minerals... Keep Reading...

Interactive Chart

Latest Press Releases

Related News